Vaxxas is developing and commercializing a high-density microarray patch (HD-MAP) as an alternative vaccine delivery technology to traditional needle and syringe. During this presentation, Vaxxas Chief Technology Officer Dr Angus Forster will discuss the opportunities and challenges to product commercialization, and provide an overview of active research and clinical programs.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2011
Main Therapeutic Focus:
Infectious Diseases
Lead Product in Development:
Covid-19 vaccine delivered to the skin using HD-MAP
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
